Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

Orsi, Giulia; Tovoli, Francesco; Dadduzio, Vincenzo; Vivaldi, Caterina; Brunetti, Oronzo; Ielasi, Luca; Conti, Fabio; Rovesti, Giulia; Gramantieri, Laura; Rizzato, Mario Domenico; Pecora, Irene; Argentiero, Antonella; Teglia, Federica; Salani, Francesca; Granito, Alessandro; Zagonel, Vittorina; Marisi, Giorgia; Cabibbo, Giuseppe; Foschi, Francesco Giuseppe; Benevento, Francesca; Cucchetti, Alessandro; Piscaglia, Fabio; Cascinu, Stefano; Scartozzi, Mario; Casadei-Gardini, Andrea

doi:10.1007/s11523-020-00757-3

Cited by 15 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last years a growing interest in the interplay between HCC, inflammatory microenvironment and circulating immune cells has emerged. [29][30][31] The present study 32 Our study demonstrates for the first time the predictive role of this peripheral cells.…”

Section: Discussionsupporting

confidence: 58%

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Rimini

Shimose

Tada

et al. 2021

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Background: Advanced Hepatocarcinoma (HCC) is an important health problem worldwide. Recently, the REFLECT trial demonstrated the non-inferiority of Lenvatinib compared to Sorafenib in I line setting, thus leading to the approval of new first-line standard of care, along with Sorafenib. Aims and methods:With aim to evaluate the optimal choice between Sorafenib and Lenvatinib as primary treatment in clinical practice, we performed a multicentric analysis with the propensity score matching on 184 HCC patients. Results:The median overall survival (OS) were 15.2 and 10.5 months for Lenvatinib and Sorafenib arm, respectively. The median progression-free survival (PFS) was 7.0 and 4.5 months for Lenvatinib and Sorafenib arm, respectively. Patients treated with Lenvatinib showed a 36% reduction of death risk (p = 0.0156), a 29% reduction of progression risk (p = 0.0446), a higher response rate (p < 0.00001) and a higher disease control rate (p = 0.002). Sorafenib showed to be correlated with more handfoot skin reaction and Lenvatinib with more hypertension and fatigue. We highlighted the prognostic role of Barcelona Clinic Liver Cancer (BCLC) stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), bilirubin, alkaline

show abstract

Section: Discussionsupporting

confidence: 58%

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Rimini

Shimose

Tada

et al. 2021

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…This cohort included a Western population from Italy, and those derived from prospectively collected data in the same setting as the lenvatinib cohort, enrolled in our previous studies. 8,[17][18][19] Then, the classification based on the five variables identified in the lenvatinib cohort was applied to this cohort. Finally, outcomes of the two therapies were compared in the three risk classes, and an interaction test was carried out.…”

Section: Methodsmentioning

confidence: 99%

Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Background: After the advent of new treatment options for advanced hepatocellular carcinoma (HCC), the identification of prognostic factors is crucial for the selection of the most appropriate therapy for each patient. Patients and methods: With the aim to fill this gap, we applied recursive partitioning analysis (RPA) to a cohort of 404 patients treated with lenvatinib. Results: The application of RPA resulted in a classification based on five variables that originated a new prognostic score, the lenvatinib prognostic index (LEP) index, identifying three groups: low risk [patients with prognostic nutritional index (PNI) >43.3 and previous trans-arterial chemoembolization (TACE)]; medium risk [patients with PNI >43.3 but without previous TACE and patients with PNI <43.3, albumin-bilirubin (ALBI) grade 1 and Barcelona Clinic Liver Cancer stage B (BCLC-B)]; high risk [patients with PNI <43.3 and ALBI grade 2 and patients with PNI <43.3, albumin-bilirubin (ALBI) grade 1 and Barcelona Clinic Liver Cancer stage C (BCLC-C)]. Median overall survival was 29.8 months [95% confidence interval (CI) 22.8-29.8 months] in low risk patients (n ¼ 128), 17.0 months (95% CI 15.0-24.0 months) in medium risk (n ¼ 162) and 8.9 months (95% CI 8.0-10.7 months) in high risk (n ¼ 114); low risk hazard ratio (HR) 1 (reference group), medium risk HR 1.95 (95% CI 1.38-2.74), high risk HR 4.84 (95% CI 3.16-7.43); P < 0.0001. The LEP index was validated in a cohort of 127 Italian patients treated with lenvatinib. While the same classification did not show a prognostic value in a cohort of 311 patients treated with sorafenib, we also show a possible predictive role in favor of lenvatinib in the low risk group. Conclusions: LEP index is a promising, easy-to-use tool that may be used to stratify patients undergoing systemic treatment of advanced HCC.

show abstract

“…A high eosinophil count is correlated with a better prognosis in hepatocellular carcinoma treated with sorafenib, in melanoma, renal carcinoma, and in colorectal, lung, cervical and pancreatic cancer. However, eosinophilia is an unfavorable prognostic marker in breast cancer and lymphoma [ 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ]. In the present study, the association between a low SII and eosinophilia in chemotherapy-naïve GCT patients was described.…”

Section: Discussionmentioning

confidence: 99%

Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammation–Index Level in Germ Cell Tumors

Kalavska

Šestáková

Mlcakova³

et al. 2022

Life

View full text Add to dashboard Cite

The tumor microenvironment (TME) and the host inflammatory response are closely interconnected. The interplay between systemic inflammation and the local immune response may influence tumor development and progression in various types of cancer. The systemic immune–inflammation index (SII) represents a prognostic marker for germ cell tumors (GCTs). The aim of the present study was to detect specific immune cell subpopulation changes which were associated with the SII level in chemotherapy-naïve GCT patients. In total, 51 GCT patients, prior to cisplatin-based chemotherapy, were included in the present study. Immunophenotyping of peripheral blood leukocyte subpopulations was performed using flow cytometry. The SII level was correlated with the percentage of various leukocyte subpopulations. The obtained results demonstrated that SII levels above the cut-off value of SII ≥ 1003 were associated with higher neutrophil percentages. An inverse correlation was found between the SII and the peripheral lymphocyte percentage that logically reflects the calculations of the SII index. Furthermore, the presented data also showed that in the lymphocyte subpopulation, the association with the SII was driven by T-cell subpopulations. In innate immunity–cell subpopulations, we observed a correlation between SII level and neutrophils as well as associations with eosinophil, basophil, natural killer cell and dendritic cell percentages. We suppose that the described interactions represent a manifestation of cancer-induced immune suppression. The results of the present study contribute to the elucidation of the interrelationship between tumor cells and the innate/adaptive immune system of the host.

show abstract

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

Cited by 15 publications

References 51 publications

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammation–Index Level in Germ Cell Tumors

Contact Info

Product

Resources

About